{
    "id": 579,
    "fullName": "PTEN wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type PTEN indicates that no mutation has been detected within the PTEN gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/15/2014",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5905,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 786,
                "therapyName": "KX2-391",
                "synonyms": null
            },
            "indication": {
                "id": 6067,
                "name": "ovarian mucinous neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5193,
                    "pubMedId": 24100628,
                    "title": "Targeting SRC and tubulin in mucinous ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24100628"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5906,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 3979,
                "therapyName": "KX2-391 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 6067,
                "name": "ovarian mucinous neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5193,
                    "pubMedId": 24100628,
                    "title": "Targeting SRC and tubulin in mucinous ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24100628"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4079,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 848,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 1341,
                "therapyName": "2-Methoxyestradiol",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 492,
                    "pubMedId": 24162827,
                    "title": "PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1\u03b1 suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24162827"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4691,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2256098 treatment resulted in a decreased response in uterine cancer cells with PTEN wild-type versus uterine cancer cells harboring a PTEN mutation (PMID: 25833835).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 3078,
                "therapyName": "GSK2256098",
                "synonyms": null
            },
            "indication": {
                "id": 363,
                "name": "uterine cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4669,
                    "pubMedId": 25833835,
                    "title": "PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25833835"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6123,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6107,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5629,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6124,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6121,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Venclexta (venetoclax) and Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5107,
                "therapyName": "Buparlisib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263) and Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5105,
                "therapyName": "Buparlisib + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Venclexta (venetoclax) and Pictilisib (GDC-0941) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 5108,
                "therapyName": "Pictilisib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) did not result in efficacy in PTEN wild-type prostate cancer cells expressing ITGA5 in culture (PMID: 27590631).",
            "molecularProfile": {
                "id": 26938,
                "profileName": "ITGA5 pos PTEN wild-type"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7353,
                    "pubMedId": 27590631,
                    "title": "Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27590631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673).",
            "molecularProfile": {
                "id": 27384,
                "profileName": "PIK3CA act mut PTEN wild-type"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3638,
                    "pubMedId": 21358673,
                    "title": "PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21358673"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10365,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673).",
            "molecularProfile": {
                "id": 27384,
                "profileName": "PIK3CA act mut PTEN wild-type"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3638,
                    "pubMedId": 21358673,
                    "title": "PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21358673"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10367,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line harboring a PIK3CA activating mutation, PIK3R1 mutation, and PTEN wild-type demonstrated sensitivity to Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673).",
            "molecularProfile": {
                "id": 27385,
                "profileName": "PIK3CA act mut PIK3R1 mut PTEN wild-type"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3638,
                    "pubMedId": 21358673,
                    "title": "PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21358673"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16719,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 30715161; NCT02423603).",
            "molecularProfile": {
                "id": 31771,
                "profileName": "AKT1 wild-type PIK3CA wild-type PTEN wild-type"
            },
            "therapy": {
                "id": 2192,
                "therapyName": "Capivasertib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14752,
                    "pubMedId": 30715161,
                    "title": "Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 683,
            "profileName": "PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19447,
            "profileName": "EGFR dec exp PTEN wild-type RICTOR dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20307,
            "profileName": "PIK3CA G106_R108del PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20308,
            "profileName": "PIK3CA K111R PIK3CA H1047R PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21308,
            "profileName": "BRAF mut PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24392,
            "profileName": "BRAF V600E PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26938,
            "profileName": "ITGA5 pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27384,
            "profileName": "PIK3CA act mut PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27385,
            "profileName": "PIK3CA act mut PIK3R1 mut PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31235,
            "profileName": "ERBB2 neg ESR1 pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31236,
            "profileName": "ERBB2 neg PGR pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31237,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31771,
            "profileName": "AKT1 wild-type PIK3CA wild-type PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}